• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

47.77 -0.44 (-0.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
3 Stocks Under $50 with Open Questions
May 21, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
3 Small-Cap Stocks That Concern Us
May 18, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Growth Stocks We Approach with Caution
May 15, 2026
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
May 12, 2026
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge ↗
May 05, 2026
Via Chartmill
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth ↗
February 24, 2026
Via Chartmill
News headline image
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
May 12, 2026
Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth produ... 
Via StockStory
Topics Earnings Supply Chain
News headline image
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
May 07, 2026
What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 6.8% in the afternoon session after the company repor... 
Via StockStory
Topics Earnings Economy
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
May 06, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
May 06, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on yea... 
Via StockStory
Topics Economy Supply Chain
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
May 06, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged... 
Via StockStory
News headline image
Supernus (SUPN) Q1 2026 Earnings Transcript ↗
May 05, 2026
Supernus (SUPN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates
May 05, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 38.6... 
Via StockStory
Topics Earnings
News headline image
Supernus Announces First Quarter 2026 Financial Results
May 05, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
May 03, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after the bell. Here’s what to look ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
April 26, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
April 22, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
April 17, 2026
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy
News headline image
3 Unprofitable Stocks We Think Twice About
April 14, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 Facing Headwinds
April 13, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
News headline image
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year ↗
March 27, 2026
Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
March 12, 2026
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, m... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
February 24, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the... 
Via StockStory
News headline image
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in March Investor Conferences
February 23, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
February 22, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
From BioMedWire
Via GlobeNewswire
News headline image
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
February 16, 2026
Supernus Pharmaceuticals’s 18.3% return over the past six months has outpaced the S&P 500 by 12.3%, and its stock price has climbed to $50.84 per share. This performance may have investors wondering... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
February 12, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap